Showing results (121-130 of 161) with videos related to
Sort By:
Pageof 17
ESMO Open|December 7, 2017
Clinical outcome and molecular characterisation of chemorefractory metastatic colorectal cancer patients with long-term efficacy of regorafenib treatmentErika Martinelli, Vincenzo Sforza, Claudia Cardone, et al.High-Throughput|February 15, 2020
Comparative Study of NGS Platform Ion Torrent Personal Genome Machine and Therascreen Rotor-Gene Q for the Detection of Somatic Variants in CancerAngela Lombardi, Margherita Russo, Amalia Luce, et al.Journal of Experimental & Clinical Cancer Research : CR|January 7, 2021
Vulnerability to low-dose combination of irinotecan and niraparib in ATM-mutated colorectal cancerPietro Paolo Vitiello, Giulia Martini, Luigi Mele, et al.Journal of Translational Medicine|August 30, 2019
Incidence and risk factors of early HCC occurrence in HCV patients treated with direct acting antivirals: a prospective multicentre studyLuca Rinaldi, Alessandro Perrella, Maria Guarino, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 12, 2008
Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumorsJosep Tabernero, Federico Rojo, Emiliano Calvo, et al.The Oncologist|May 10, 2018
Trifluridine/Tipiracil (TAS-102) in Refractory Metastatic Colorectal Cancer: A Multicenter Register in the Frame of the Italian Compassionate Use ProgramChiara Cremolini, Daniele Rossini, Erika Martinelli, et al.Therapeutic Advances in Medical Oncology|May 13, 2022
Comprehensive genome profiling by next generation sequencing of circulating tumor DNA in solid tumors: a single academic institution experienceVincenza Caputo, Vincenzo De Falco, Anna Ventriglia, et al.Future Oncology (London, England)|March 5, 2021
Italian results of the PRECONNECT study: safety and efficacy of trifluridine/tipiracil in metastatic colorectal cancerAlberto Zaniboni, Carlo Antonio Barone, Maria Chiara Banzi, et al.Journal of Experimental & Clinical Cancer Research : CR|March 29, 2022
Anti-tumor activity of cetuximab plus avelumab in non-small cell lung cancer patients involves innate immunity activation: findings from the CAVE-Lung trialCarminia Maria Della Corte, Morena Fasano, Vincenza Ciaramella, et al.The Oncologist|April 7, 2019
HER2 Positivity Predicts Unresponsiveness to EGFR-Targeted Treatment in Metastatic Colorectal CancerAndrea Sartore-Bianchi, Alessio Amatu, Luca Porcu, et al.Pageof 17